Pham Ngoc Thach University of Medicine   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Ho Chi Minh City Vietnam (2008)

Organization Overview

First Clinical Trial
2010
NCT00651066
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pham Ngoc Thach University of Medicine

Active Ingredients

Drugs in Phase 4 Trials (1)

albendazole (Albenza) (2 trials)

Drugs in Phase 3 Trials (1)

urea (2 trials)

Drugs in Phase 2 Trials (3)

lopinavir (Kaletra) (1 trial)

rifabutin (mycobutin) (1 trial)

ritonavir (Norvir) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Chemical and Drug Induced Liver Injury (Phase 3)

Communicable Diseases (Phase 2)

Diarrhea (Phase 4)

Helminthiasis (Phase 4)

HIV Infections (Phase 2)

Infections (Phase 2)

Meningitis (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Meningeal (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5